Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell ...

The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...

In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how ...

With data from the Phase III STELLAR-303 study in third-line metastatic colorectal cancer in the books, Exelixis is plotting ...

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in ...

Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...

The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according ...

To tailor cancer therapies to individual patients, Moderna, BioNTech and other companies are rethinking how they optimize ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Last month, investors' hopes were dashed as Replimune suggested alignment had not yet been reached with the FDA on RP1’s future. Now, the regulator has accepted a refiled application after all.

Glaukos’ Epioxa allows cross-linking therapy for keratoconus without requiring an incision. The biotech expects to launch the ...

Rybelsus can now be used as a primary or secondary prevention pill to lower the risk of major adverse cardiovascular events ...